Abstracts tagged "Women’s health"

Abstract Number: 1720 • ACR Convergence 2021
Cervical Dysplasia and HPV Infection in Women with Vasculitis
Taylor Koenig¹, Ambra Burrell², Hilary Kleppel³, Ashlee Weaver⁴, Veronica Mruk⁵, Lynn Fussner¹, Salem Almaani⁶ and Alexa Meara¹, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Division of Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Wright State University, Blacklick, OH, ⁴Ohio State University College of Medicine, Columbus, OH, ⁵Ohio State University / Nationwide Children's Hospital, Columbus, OH, ⁶Ohio State University Medical Center, Columbus, OH
Background/Purpose: The most common cause of cervical cancer is persistent human papillomavirus (HPV) infection in the cervical epithelium, causing precancerous cervical dysplasia and ultimately cervical…
Abstract Number: 1721 • ACR Convergence 2021
A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases
Lauren He, Rachel Karani, Gabriel Arenas and Cuoghi Edens, University of Chicago, Chicago, IL
Background/Purpose: Reproductive age women with rheumatic diseases are commonly cared for by non-rheumatologists who provide contraceptive counseling, preconception, pregnancy, and post-partum management. When women’s health…
Abstract Number: 0133 • ACR Convergence 2021
Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus
Erica Rosen¹ and Megan Krause², ¹University of Kansas, Kansas City, MO, ²University of Kansas, Kansas City, KS
Background/Purpose: Females with systemic lupus erythematosus have increased rates of cervical cancer especially if on immunosuppressive therapy. The American Cancer Society reports the incidence of…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 0580 • ACR Convergence 2021
Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women
Yeonghee Eun¹, In Young Kim², Kyungdo Han³, Kyu Na Lee³, Dong-Yun Lee¹, Dong Wook Shin¹, Seonyoung Kang¹, Seulkee Lee¹, Hoon-Suk Cha¹, Eun-Mi Koh¹, Jaejoon Lee¹ and Hyungjin Kim¹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²National Police Hospital, Seoul, Republic of Korea, ³Soongsil University, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that the incidence and risk factors of gout differs according to sex. However, little research has been done on the…
Abstract Number: 0619 • ACR Convergence 2021
Racial and Ethnic Disparities in Pregnancy Outcomes Among Women with Rheumatic Diseases: A Systematic Literature Review and Quantitative Analysis
Maya Swaminathan¹, Gloria Shen², Irvin Huang², Diana Louden², Waqas Tahir³ and Namrata Singh⁴, ¹MultiCare Good Samaritan Hospital, Newcastle, WA, ²University of Washington, Seattle, WA, ³Rochester General Hospital, Rochester, MN, ⁴University of Washington, Bellevue, WA
Background/Purpose: Women are disproportionately affected by rheumatic diseases (RD), with many of them carrying the diagnosis in their childbearing years. Pregnant women with RD have…
Abstract Number: 0636 • ACR Convergence 2021
Contraceptive and Pre-conception Counseling in an Academic Rheumatology Practice: A Needs Assessment to Identify Gaps in Care
Tara Skorupa¹, Guiset Carvajal², Kristin Sturm¹, Ju Young Kwag³, JoAnn Zell¹ and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Colorado, CO, ³University of Colorado, Denver, CO
Background/Purpose: Systemic autoimmune conditions affect women of childbearing age, and teratogenic medications are commonly prescribed as treatment. In this study, we surveyed rheumatology patients to…
Abstract Number: 0538 • ACR Convergence 2020
Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study
Madeline Peterson¹, Thomas O'Byrne¹, John Davis¹, Vanessa Kronzer¹, Lynne Peterson¹, Michael Weisman² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: The long-term safety of breast implants has been a debated topic; two recent studies have raised new concerns about their potential negative health effects…
Abstract Number: 0574 • ACR Convergence 2020
Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
Katherine Pryor¹, Chang Xu¹, Jamie Collins¹, Karen Costenbader² and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine/chloroquine (HCQ/CQ) is considered to be the backbone of systemic lupus erythematosus (SLE) care. Differences in receipt of HCQ/CQ may exacerbate disparities in adverse…
Abstract Number: 0917 • ACR Convergence 2020
Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Madelon Vonk¹, Mandy Avis², Kristell Marzin³, Salome Mack³, Sven Wind³ and Martina Gahlemann⁴, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Boehringer Ingelheim B.V., Alkmaar, The Netherlands, Alkmaar, Netherlands, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that has been approved for the treatment of SSc-ILD. As nintedanib may cause fetal harm, patients taking nintedanib…
Abstract Number: 0938 • ACR Convergence 2020
Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Cecilia Nalli¹, Daniele Lini², Laura Andreoli², Francesca Crisafulli², Micaela Fredi², Maria Grazia Lazzaroni², Victoria Bitsadze³, Antonia Calligaro⁴, Valentina Canti⁵, Roberto Caporali⁶, Francesco Carubbi⁷, Cecilia Chighizola⁸, Paola Conigliaro⁹, Caterina De Carolis¹⁰, Teresa Del Ross⁴, Maria Favaro⁴, Maria Gerosa¹¹, Annamaria Iuliano¹², Jamilya Khizroeva³, Alexander Makatsariya³, Pierlugi Meroni¹³, Marta Mosca¹⁴, Melissa Padovan¹⁵, Roberto Perricone⁹, Patrizia Rovere-Querini¹⁶, Gian Domenico Sebastiani¹², Chiara Tani¹⁴, Marta Tonello⁴, Dina Zucchi¹⁴, Franco Franceschini¹⁷ and Angela Tincani², ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Department of Obstetrics and Gynecology of I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁴Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy, ⁵Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁸Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Experimental Laboratory of Immunorheumatological Researches, Istituto Auxologico Italiano, Milan, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹⁰Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹¹Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milan, Italy, ¹²Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹³Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵UO e Sezione di Reumatologia, Dipartimento di Scienze Mediche, Universita' degli Studi di Ferrara, Ferrara, Italy, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Milan, Italy, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: The role of complement in the aPL related pathology has been widely studied in animal models. aPL can induce fetal loss in experimental animals but…
Abstract Number: 1006 • ACR Convergence 2020
Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort
Carine Salliot¹, Yann Nguyen², Amandine Gelot³, Xavier Mariette⁴, Marie-Christine Boutron-Ruault³ and Raphaèle Seror⁵, ¹CHR orleans, Orleans, France, ²1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ³Institut Gustave Roussy, Villejuif, France, ⁴Paris-Sud University, Rueil-Malmaison, France, ⁵Rheumatology Department, Bicetre Hospital, APHP, France, Paris, France
Background/Purpose: The involvement of female hormones in the pathogenesis of Rheumatoid Arthritis (RA) is supported by numerous observations: a female predominance, an increased incidence in…
Abstract Number: 1257 • ACR Convergence 2020
Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Sofia Gernaat¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Stanford Medicine, Stanford, CA, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Increased insulin resistance is pivotal in the development of gestational diabetes mellitus (GDM). Women with SLE may be at higher risk of GDM due…
Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Megan Clowse¹, Jing Li², Amanda Eudy³, Mehret Birru Talabi⁴ and Gabriela Schmajuk⁵, ¹Duke University, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of California, San Francisco, Atherton, CA
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
Abstract Number: 1621 • ACR Convergence 2020
Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care
Mehret Birru Talabi¹, Kwonho Jeong¹, Kaleab Abebe¹, Megan Clowse², Robyn Domsic³ and Sonya Borrero¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Duke University, Chapel Hill, NC, ³University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Cervical cancer screening is important for women with systemic lupus erythematosus (SLE) and women prescribed TNF-alpha inhibitors (TNFi), as they have an increased risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].